Company Filing History:
Years Active: 2018
Title: Innovations by Inventor John Löblom
Introduction
John Löblom is an inventive mind based in Huddinge, Sweden. He has made significant strides in the field of engineered polypeptides, having been awarded a patent that underscores his contribution to biopharmaceutical innovation.
Latest Patents
Löblom holds a patent related to a class of engineered polypeptides that exhibit a binding affinity for the neonatal Fc receptor, known as FcRn. The patent outlines an FcRn binding polypeptide characterized by the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX (SEQ ID NO: 1075). Moreover, it discusses the applications of this polypeptide as a means to modify both pharmacokinetic and pharmacodynamic properties, positioning it as a potential therapeutic agent.
Career Highlights
John Löblom is a notable employee at Affibody AB, a company renowned for its focus on developing innovative therapeutics. His work in the realm of engineered polypeptides highlights his initiative and expertise in biochemistry and molecular biology, demonstrating a commitment to advancing medical science.
Collaborations
In his professional journey, Löblom has collaborated with colleagues such as Caroline Ekblad and Elin Gunneriusson, contributing to a collaborative environment that promotes innovation and research excellence at Affibody AB.
Conclusion
John Löblom's contributions through his patent on engineered polypeptides are a testament to his innovative spirit in the biomedical field. By intertwining scientific research with practical applications, he is paving the way for new therapeutic options that could significantly impact patient care. His collaborative efforts further enrich the landscape of innovation at Affibody AB, solidifying his role as a key player in the field of biopharmaceuticals.